{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:37Z","timestamp":1753891957536,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is a kind of peripheral T-cell lymphomas (PTCLs) with a highly invasive feature. At present, patients are often treated with CHOP or CHOP-like regimens which is of poor prognosis whilst having high recurrence rate. Once the patient fails to achieve remission or relapse after the first-line treatment, many salvage chemotherapy regimens are always ineffective, and the long-term survival will be difficult to achieve for them. In this circumstance, more effective therapy methods are needed. In this study, two patients with relapsed\/refractory AITL were treated with the CAOLD regimen [cyclophosphamide 400\u00a0mg\/m<jats:sup>2<\/jats:sup> qd d1, cytarabine 30\u00a0mg\/m<jats:sup>2<\/jats:sup> qd d1\u2013d4, vindesine 2\u00a0mg\/m<jats:sup>2<\/jats:sup> qd d1, pegaspargase (PEG-ASP) 2,500\u00a0IU\/m<jats:sup>2<\/jats:sup> qd d2, dexamethasone 7.5\u00a0mg\/m<jats:sup>2<\/jats:sup> qd d1\u2013d5], and long-term remission was achieved after chemotherapy. One is still alive after achieving complete remission (CR) after two cycles of chemotherapy, who has been followed up for 82\u00a0months. Besides, another patient achieved partial remission (PR) after the first course of chemotherapy. Then, CR was obtained after four courses of consolidation chemotherapy. The patient has been followed up for 63\u00a0months and is still alive. Both of them achieved long-time survival. These two successful cases demonstrated that the CAOLD regimen can be a better choice for relapsed\/refractory AITL and offers hope of breakthrough in this medical field.<\/jats:p>","DOI":"10.3389\/fonc.2021.758445","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T05:02:44Z","timestamp":1641186164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed\/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liren","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-Cell Lymphoma: The Many-Faced Lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.12.001","article-title":"Angioimmunoblastic T-Cell Lymphoma","volume":"31","author":"Broccoli","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00511","article-title":"Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma","volume":"15","author":"Moskowitz","year":"2019","journal-title":"J Oncol Pract"},{"key":"B5","article-title":"Report of the Committee on Hodgkin\u2019s Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A Predictive Model for Aggressive non-Hodgkin\u2019s Lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous Stem-Cell Transplantation as First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-Reinforced-ABVD (VIP-rABVD) is Not Superior to CHOP\/21 in Newly Diagnosed Peripheral T Cell Lymphoma. Results of the Randomized Phase III Trial GOELAMS-Ltp95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of Peripheral T-Cell Lymphomas in a Single North American Institution by the WHO Classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-World Data on Prognostic Factors and Treatment in Peripheral T-Cell Lymphomas: A Study From the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: An Analysis of Patients With T-Cell Lymphoma Treated in Studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP Chemotherapy as First-Line Treatment of Peripheral T-Cell Lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Prospective Multicenter Trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054833","article-title":"Peripheral Blood Progenitor Cell Mobilization With Dexa-Beam\/G-CSF, Ether Lipid Purging, and Autologous Transplantation After High-Dose CBV Treatment: A Safe and Effective Regimen in Patients With Poor Risk Malignant Lymphomas","volume":"23","author":"Knauf","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of Romidepsin With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Patients With Peripheral T-Cell Lymphoma: A non-Randomised, Phase 1b\/2 Study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in Combination With CHOP as First-Line Treatment for Patients With Stage III\/IV Peripheral T-Cell Lymphomas: A Multicentre, Single-Arm, Phase 2 Trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 Expression in Peripheral T-Cell Lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin With Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05694.x","article-title":"Selective Apoptosis of Natural Killer-Cell Tumours by L-Asparaginase","volume":"130","author":"Ando","year":"2005","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)\/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for Natural Killer\/T-Cell Lymphoma: Analysis of Safety and Efficacy From the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"B21","article-title":"Clinical Analysis and Prognostic Significance of L-Asparaginase Containing Multidrug Chemotherapy Regimen in Incipient Peripheral T-Cell Lymphoma","volume":"8","author":"Yao","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.4083","article-title":"L-Asparaginase-Induced Complete Response in a Relapsed Patient With Epstein-Barr Virus and Cytotoxic Peripheral T-Cell Lymphoma Not Otherwise Specified","volume":"49","author":"Takahashi","year":"2010","journal-title":"Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.14740\/jh459w","article-title":"Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed\/Refractory T-Cell Lymphoma","volume":"7","author":"Norasetthada","year":"2018","journal-title":"J Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.758445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T05:02:48Z","timestamp":1641186168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.758445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":23,"alternative-id":["10.3389\/fonc.2021.758445"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.758445","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"758445"}}